Market Access in Canada and Challenges for Orphan and Ultra-Orphan Diseases
Healthcare in Canada has been identified as being fragmented, and obtaining Market Access is cumbersome and lengthy. Rare diseases are a complex issue but account for a large amount of healthcare spending. Currently there is no orphan medicine framework in Canada. Planned changes announced by the Patented Medicines Pricing and Review Board (PMPRB) to promote fair and equal pricing to medicines, may see the prices of drugs for rare diseases being reduced significantly, making Canada a less attractive market for pharma in the future.
Read more on the MAP market access blog: https://www.mappatientaccess.com/blog/?post=market-access-in-canada
OpenEdition vous propose de citer ce billet de la manière suivante :
egennet (17 mai 2022). Market Access in Canada and Challenges for Orphan and Ultra-Orphan Diseases. ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/o5zc





